The ability of this agent to decrease both HIF-1α and HIF-2α levels combined with its anti-angiogenic and anti-vascular properties suggest that it may have significant efficacy against highly vascularized tumors such as RCC. The gene discussed is HIF1A; the disease is renal cell carcinoma.